Significant improvements in full year 2022 Adjusted EBITDA PMPM, with Strong revenue growth of 46% for the fourth quarter and 32% for full year 2021
第四季度收入強勁增長46％，2021年全年收入增長32％
Full year 2022 revenue expected to be up to $1 billion, a 56% increase vs. prior year
2022年全年收入預計將高達10億美元，比上年增長56％
At-risk Medicare Advantage members expected to be up 95,000 by end of full year 2022, a 42% increase vs. prior year
預計到2022年全年底，有風險的Medicare Advantage成員將增加9.5萬人，比上年增長42％
Significant improvements in full year 2022 Adjusted EBITDA PMPM, with
Adjusted EBITDA profitability expected in 2024
2022年全年調整後的息稅折舊攤銷前利潤PMPM有了顯著改善，其中
調整後的息稅折舊攤銷前利潤預計將在2024年實現盈利
HENDERSON, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners, Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its select preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2021, along with its full year 2022 outlook in advance of the Company's upcoming participation at several investor conferences in March.
內華達州亨德森，2022年3月9日（GLOBE NEWSWIRE）——以患者爲中心、由醫生主導的人口健康管理公司P3 Health Partners, Inc.（“P3” 或 “公司”）（納斯達克股票代碼：PIII）今天宣佈了截至2021年12月31日的第四季度和全年未經審計的部分初步財務業績和業務更新，以及公司發佈2022年全年展望即將參加三月份的幾次投資者會議。
"Our preliminary results for 2021 demonstrate continued progress on our strategic objectives, which we believe provides a solid foundation for P3 Health Partners in 2022," said Dr. Sherif Abdou, CEO of P3 Health Partners. "Our 2021 revenue is expected to be $642 million, an increase of 32% from the prior year, exceeding our full-year guidance as we grew our at-risk Medicare Advantage members to 67,000 at year-end. We also continued our national expansion with our entry into California announced earlier this year, and we're now operating in 5 states and 18 markets as of January 2022."
P3 Health Partners首席執行官謝里夫·阿卜杜博士說：“我們2021年的初步業績表明我們的戰略目標持續取得進展，我們認爲這爲2022年P3 Health Partners提供了堅實的基礎。”“我們2021年的收入預計爲6.42億美元，比上年增長32％，超過了我們的全年預期，因爲我們在年底將有風險的Medicare Advantage會員人數增加到67,000人。今年早些時候，我們宣佈進入加利福尼亞州，從而繼續在全國範圍內擴張，截至2022年1月，我們目前在5個州和18個市場開展業務。”
Dr. Abdou continued, "We anticipate 2022 revenue to reach up to approximately $1 billion, a 56% increase over the prior year and well ahead of our previous estimate of $825 million, driven by up to 95,000 at-risk Medicare Advantage members by year-end, representing a 42% increase over the prior year. On the bottom line, we expect a 50% improvement in adjusted EBITDA per member per month (PMPM) at the midpoint of our guidance. Our balance sheet remains strong, with approximately $140 million in cash at the end of December 2021, providing ample capital until we achieve profitable adjusted EBITDA in 2024."
阿卜杜博士繼續說：“我們預計2022年的收入將達到約10億美元，比上年增長56％，遠高於我們之前估計的8.25億美元，這要歸因於到年底有多達9.5萬名處境危險的Medicare Advantage會員，比上年增長42％。總而言之，我們預計，調整後的每位會員每月息稅折舊攤銷前利潤（PMPM）將在我們的指導中點提高50％。我們的資產負債表仍然強勁，截至2021年12月底，現金約爲1.4億美元，爲我們在2024年實現調整後的息稅折舊攤銷前利潤實現盈利之前提供了充足的資本。”
Select Preliminary Unaudited Financial Results
Fourth Quarter 2021:
選擇未經審計的初步財務業績
2021 年第四季度：
- Revenue is expected to increase 46% to approximately $183 million compared to $125 million in the prior year.
- Net loss is expected to range between approximately $90 million and $95 million compared to a net loss of $14.2 million in the prior year.
- Adjusted EBITDA loss (a non-GAAP number defined herein) is expected to range between approximately $35 million and $30 million compared to an adjusted EBITDA loss of $30 million in the prior year.(1)
- 與去年同期的1.25億美元相比，收入預計將增長46％，達到約1.83億美元。
- 淨虧損預計在9000萬美元至9500萬美元之間，而去年的淨虧損爲1,420萬美元。
- 調整後的息稅折舊攤銷前利潤虧損（此處定義的非公認會計准則數字）預計將在約3500萬美元至3000萬美元之間，而去年調整後的息稅折舊攤銷前利潤虧損爲3000萬美元。（1)
Full Year 2021 vs. 2020:
2021 年全年對比 2020 年：
- At-risk Medicare Advantage members at December 31, 2021, increased approximately 32% to 67,000 compared to 51,000 in the prior year. (2)
- Revenue is expected to increase 32% to approximately $642 million compared to $486 million in the prior year.
- Net loss is expected to range between approximately $176 million and $181 million compared to a net loss of $45.4 million in the prior year.
- Net loss PMPM is expected to range between $248 and $242.
- Adjusted EBITDA loss is expected to range between $88 million and $83 million compared to an adjusted EBITDA loss of $55 million in the prior year. (1)
- Adjusted EBITDA loss PMPM is expected to range between $120 and $115. (1)
- 截至2021年12月31日，有風險的Medicare Advantage會員增長了約32％，達到6.7萬人，而去年同期爲51,000人。 (2)
- 與去年同期的4.86億美元相比，收入預計將增長32％，達到約6.42億美元。
- 淨虧損預計在1.76億美元至1.81億美元之間，而去年的淨虧損爲4,540萬美元。
- 預計淨虧損PMPM將在248美元至242美元之間。
- 調整後的息稅折舊攤銷前利潤虧損預計將在8,800萬美元至8,300萬美元之間，而去年調整後的息稅折舊攤銷前利潤虧損爲5,500萬美元。 (1)
- 調整後的息稅折舊攤銷前利潤虧損PMPM預計將在120美元至115美元之間。 (1)
(1) Adjusted EBITDA and Adjusted EBITDA PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures and more information regarding the Company's use of non-GAAP financial measures, please see the section titled "Non-GAAP Financial Measures."
(2) See "Key Performance Metrics" for additional information on how the Company defines "at-risk Medicare Advantage members."
Full Year 2022 Outlook:
The Company expects full year 2022 revenue between $950 million and $1.0 billion, representing a 48% to 56% increase over the prior year. The Company expects at-risk Medicare Advantage members between 90,000 and 95,000, at December 31, 2022, representing a 34% to 42% increase over the prior year. P3 also expects adjusted EBITDA loss to range between $80 million and $50 million reflecting our expected high growth rate and the underlying improving operating performance, offset by incremental labor expenses related to front line staff, such as nurses, and continued expenses related to COVID-19. On a PMPM basis, full year 2022 adjusted EBITDA loss is expected to improve to $75 PMPM to $45 PMPM compared to an expected range of $120 PMPM to $115 PMPM in the prior year, representing a 35% to 63% improvement versus the prior year.
(1) 調整後的息稅折舊攤銷前利潤和調整後的息稅折舊攤銷前利潤PMPM是非公認會計准則財務指標。有關這些指標與最直接可比的公認會計准則指標的對賬情況以及有關公司使用非公認會計准則財務指標的更多信息，請參閱標題爲 “非公認會計准則財務指標” 的部分。
(2) 有關公司如何定義 “處境危險的Medicare Advantage會員” 的更多信息，請參閱 “關鍵績效指標”。
全年 2022 年展望：
該公司預計，2022年全年收入在9.5億美元至10億美元之間，比上年增長48％至56％。該公司預計，截至2022年12月31日，處境危險的Medicare Advantage成員在9萬至9.5萬人之間，比上年增長34％至42％。P3還預計，調整後的息稅折舊攤銷前利潤虧損將在8000萬美元至5000萬美元之間，這反映了我們預期的高增長率和潛在的經營業績改善，但被與護士等一線員工相關的增量勞動力支出以及與 COVID-19 相關的持續支出所抵消。按PMPM計算，2022年全年調整後的息稅折舊攤銷前利潤虧損預計將提高至每分鐘75美元至45美元，而上一年的預期範圍爲120美元至115美元，與去年同期相比增長35％至63％。
While the Company expects the impact of COVID-19 on our future results to be transitory, P3 expects to incur additional COVID-19 related costs in full year 2022 given the volume of positive cases and "breakthrough" cases (positive cases in vaccinated patients) present in the Company's markets. COVID-19 disproportionately impacts older adults, especially those with chronic illnesses, which describes many of P3's patients. The full extent to which COVID-19 will directly or indirectly impact P3's full year 2022 results of operations and financial condition will depend on multiple factors, including, but not limited to new and emerging information from the impact of new variants of the virus. Because of these factors, management may not be able to fully estimate the length or severity of the impact of the pandemic on P3's business and results of operations.
儘管公司預計 COVID-19 對我們未來業績的影響將是暫時的，但鑑於公司市場上存在大量陽性病例和 “突破性” 病例（接種疫苗患者的陽性病例），P3預計將在2022年全年產生額外的與 COVID-19 相關的費用。COVID-19 對老年人的影響尤其嚴重，尤其是那些患有慢性病的人，這描述了許多 P3 患者。COVID-19 將在多大程度上直接或間接地影響P3的2022年全年經營業績和財務狀況將取決於多種因素，包括但不限於來自病毒新變種影響的新興信息。由於這些因素，管理層可能無法完全估計疫情對項目組合業務和經營業績影響的持續時間或嚴重程度。
Dr. Abdou added, "In 2022, we will continue to focus on operational excellence, delivering improved patient outcomes and executing on our disciplined, purposeful growth strategy. We believe P3 is now in an excellent position to achieve our vision to lead the transformation of healthcare with our proven, capital-efficient, scalable model."
The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, no later than April 1, 2022, which will provide the Company with a 15-calendar day extension to file its Form 10-K. The Company expects to report fourth quarter and audited full year 2021 financial results on or before April 15, 2022, the expiration date of the extension period. The Company began publicly trading on the Nasdaq on December 3, 2021, and the Company and its independent auditor, BDO LLP, anticipate needing additional time to finalize the Company's initial Form 10-K filing. The Company does not expect future delays in subsequent regulatory filings.
阿卜杜博士補充說：“在2022年，我們將繼續專注於卓越運營，改善患者預後，並執行我們嚴格、有針對性的增長戰略。我們相信，P3現在完全有能力實現我們的願景，即通過我們久經考驗、資本效率高、可擴展的模式引領醫療保健行業的轉型。”
公司目前預計不遲於2022年4月1日提交12b-25表格 “逾期申報通知”，這將使公司延期15個日曆日提交其10-K表格。公司預計將在延期到期日2022年4月15日當天或之前公佈第四季度和經審計的2021年全年財務業績。公司於2021年12月3日開始在納斯達克公開交易，公司及其獨立核數師BDO LLP預計需要更多時間來完成公司的首次10-K表申報。該公司預計後續的監管文件將來不會出現延遲。
About P3 Health Partners
P3 is a patient-centered and physician-led population health management company. Founded and led by physicians, P3 is a team of doctors, clinicians and support service professionals with a shared passion for delivering value-based care. We leverage our deeply integrated and capital efficient care model, data and technology, physician leadership and community outreach tools to create enhanced patient outcomes and experiences, greater satisfaction for providers and caregivers and lower care costs. For more information, visit p3hp.org.
關於 P3 健康合作伙伴
P3 是一家以患者爲中心、由醫生主導的人口健康管理公司。P3 由醫生創立和領導，是一支由醫生、臨床醫生和支持服務專業人員組成的團隊，他們對提供基於價值的護理有着共同的熱情。我們利用深度整合和資本高效的護理模式、數據和技術、醫生領導力和社區宣傳工具，創造更好的患者療效和體驗，提高提供者和護理人員的滿意度並降低護理成本。欲了解更多信息，請訪問 p3hp.org。
Business Combination and Presentation of Financial Results
As a result of the business combination consummated on December 3, 2021, the Company was deemed to be the acquirer and successor for accounting purposes, and P3 Health Group Holdings, LLC, which is the business conducted prior to the closing of the business combination, was deemed to be the acquiree and accounting predecessor. The Company's financial results are distinguished between two distinct periods, the period prior to the business combination closing date (the "Predecessor" period) and the period after the closing date (the "Successor" period), which reflects a new basis of accounting that is based on the fair value of net assets acquired. The preliminary financial results for the quarter and year ended December 31, 2021, presented in this release combine these two periods.
業務合併和財務業績的列報
由於業務合併於2021年12月3日完成，出於會計目的，公司被視爲收購方和繼任者，而在業務合併結束之前開展的業務P3 Health Group Holdings, LLC被視爲收購方和會計前身。公司的財務業績分爲兩個不同的時期，即業務合併截止日之前的時期（“前身” 時期）和收盤日之後的時期（“繼任期”），這反映了基於收購淨資產公允價值的新會計基礎。本新聞稿中公佈的截至2021年12月31日的季度和年度的初步財務業績合併了這兩個時期。
Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures as defined by the SEC rules. Adjusted EBITDA has not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). EBITDA is defined as GAAP net income (loss) before (i) interest expense, (ii) income taxes and (iii) depreciation and amortization. Adjusted EBITDA is defined as EBITDA, further adjusted to add back the effect of certain expenses, such as (iv) mark-to-market warrant expense, (v) premium deficiency reserves, (vi) stock-based compensation and (vii) transaction expenses. Adjusted EBITDA PMPM is defined as Adjusted EBITDA divided by the number of at-risk Medicare Advantage members each month divided by the number of months in the period. We believe these non‐GAAP financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other similar companies. We do not consider these non‐GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non‐GAAP financial measures. In addition, other companies may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. The following tables present a reconciliation of Adjusted EBITDA to net income (loss) and Adjusted EBITDA PMPM to net income (loss) PMPM, which are the most directly comparable financial measures calculated in accordance with GAAP:
非公認會計准則財務指標
本新聞稿包含美國證券交易委員會規則定義的某些非公認會計准則財務指標。調整後的息稅折舊攤銷前利潤不是根據美國公認會計原則（“GAAP”）編制的。息稅折舊攤銷前利潤定義爲扣除（i）利息支出、（ii）所得稅和（iii）折舊和攤銷前的GAAP淨收益（虧損）。調整後的息稅折舊攤銷前利潤定義爲息稅折舊攤銷前利潤，進一步調整以加上某些支出的影響，例如（iv）按市值計價的認股權證支出，（v）保費缺口準備金，（vi）股票薪酬和（vii）交易費用。調整後的息稅折舊攤銷前利潤PMPM的定義爲調整後的息稅折舊攤銷前利潤除以每月面臨風險的Medicare Advantage成員人數除以該期間的月數。我們認爲，這些非公認會計准則財務指標爲投資者提供了額外的工具，可用於評估持續的經營業績和趨勢，以及將我們的財務指標與其他類似公司進行比較。我們不會孤立地考慮這些非公認會計准則指標，也不會將其作爲根據公認會計原則確定的財務指標的替代方案。這些非公認會計准則財務指標受到固有的限制，因爲它們反映了管理層對在確定這些非公認會計准則財務指標時排除或包括哪些支出和收入的判斷。此外，其他公司可能會以不同的方式計算非公認會計准則財務指標，或者可能使用其他指標來評估其業績，所有這些都可能降低我們的非公認會計准則財務指標作爲比較工具的用處。下表顯示了調整後息稅折舊攤銷前利潤與淨收益（虧損）和調整後息稅折舊攤銷前利潤（PMPM）與淨收益（虧損）PMPM 的對賬情況，這是根據公認會計原則計算的最直接可比的財務指標：
| In millions $ | Preliminary | ||||||||
| For the three months ended | For the three months ended | ||||||||
| December 31, 2021 | December 31, 2020 | ||||||||
| Lower range | Upper range | ||||||||
| Net income (loss) | $ | (94.6 | ) | $ | (89.6 | ) | $ | (14.2 | ) |
| Interest (income) expense, net | 4.2 | 4.2 | 3.1 | ||||||
| Income tax expense(1) | -- | -- | 0.1 | ||||||
| Depreciation expense | 0.5 | 0.5 | 0.2 | ||||||
| Amortization expense | 7.3 | 7.3 | -- | ||||||
| Mark-to-market warrant expense | (0.9 | ) | (0.9 | ) | -- | ||||
| Premium deficiency reserve | 5.7 | 5.7 | (19.2 | ) | |||||
| Transaction expense, Business Combinations | 24.7 | 24.7 | -- | ||||||
| Transaction related litigation fees | 7.9 | 7.9 | -- | ||||||
| Stock-based compensation | 10.2 | 10.2 | (0.2 | ) | |||||
| Adjusted EBITDA | $ | (35.0 | ) | $ | (30.0 | ) | $ | (30.2 | ) |
| 以百萬美元計 | 初步的 | ||||||||
| 在結束的三個月裏 | 在結束的三個月裏 | ||||||||
| 2021年12月31日 | 2020年12月31日 | ||||||||
| 較低的射程 | 上限範圍 | ||||||||
| 淨收益（虧損） | $ | (94.6) | ) | $ | (89.6) | ) | $ | (14.2 | ) |
| 利息（收入）支出，淨額 | 4.2 | 4.2 | 3.1 | ||||||
| 所得稅支出(1) | -- | -- | 0.1 | ||||||
| 折舊費用 | 0.5 | 0.5 | 0.2 | ||||||
| 攤銷費用 | 7.3 | 7.3 | -- | ||||||
| 按市值計價的認股權證費用 | (0.9) | ) | (0.9) | ) | -- | ||||
| 保費缺口準備金 | 5.7 | 5.7 | (19.2 | ) | |||||
| 交易費用、業務合併 | 24.7 | 24.7 | -- | ||||||
| 與交易相關的訴訟費 | 7.9 | 7.9 | -- | ||||||
| 基於股票的薪酬 | 10.2 | 10.2 | (0.2 | ) | |||||
| 調整後 EBITDA | $ | (35.0) | ) | $ | (30.0 | ) | $ | (30.2) | ) |
| In millions $ | Preliminary Unaudited | ||||||||
| For the year ended | For the year ended | ||||||||
| December 31, 2021 | December 31, 2020 | ||||||||
| Lower range | Upper range | ||||||||
| Net income (loss) | $ | (180.9 | ) | $ | (175.9 | ) | $ | (45.4 | ) |
| Interest (income) expense, net | 17.4 | 17.4 | 10.0 | ||||||
| Income tax expense(1) | -- | -- | 0.1 | ||||||
| Depreciation expense | 1.7 | 1.7 | 0.8 | ||||||
| Amortization expense | 7.3 | 7.3 | -- | ||||||
| Mark-to-market warrant expense | 11.1 | 11.1 | -- | ||||||
| Premium deficiency reserve | 10.3 | 10.3 | (20.5 | ) | |||||
| Transaction expense, Business Combinations | 25.6 | 25.6 | -- | ||||||
| Transaction related litigation fees | 7.9 | 7.9 | -- | ||||||
| Stock-based compensation | 11.6 | 11.6 | 0.4 | ||||||
| Adjusted EBITDA | $ | (88.0 | ) | $ | (83.0 | ) | $ | (54.6 | ) |
| 以百萬美元計 | 初步未經審計 | ||||||||
| 截至該年度 | 截至該年度 | ||||||||
| 2021年12月31日 | 2020年12月31日 | ||||||||
| 較低的射程 | 上限範圍 | ||||||||
| 淨收益（虧損） | $ | (180.9) | ) | $ | (175.9) | ) | $ | (45.4) | ) |
| 利息（收入）支出，淨額 | 17.4 | 17.4 | 10.0 | ||||||
| 所得稅支出(1) | -- | -- | 0.1 | ||||||
| 折舊費用 | 1.7 | 1.7 | 0.8 | ||||||
| 攤銷費用 | 7.3 | 7.3 | -- | ||||||
| 按市值計價的認股權證費用 | 11.1 | 11.1 | -- | ||||||
| 保費缺口準備金 | 10.3 | 10.3 | (20.5) | ) | |||||
| 交易費用、業務合併 | 25.6 | 25.6 | -- | ||||||
| 與交易相關的訴訟費 | 7.9 | 7.9 | -- | ||||||
| 基於股票的薪酬 | 11.6 | 11.6 | 0.4 | ||||||
| 調整後 EBITDA | $ | (88.0) | ) | $ | (83.0) | ) | $ | (54.6) | ) |
| In PMPM $ | Preliminary Unaudited | |||||
| For the year ended | ||||||
| December 31, 2021 | ||||||
| Lower range | Upper range | |||||
| Net income (loss) PMPM | $ | (248 | ) | $ | (242 | ) |
| Interest (income) expense, net | 24 | 24 | ||||
| Income tax expense(1) | -- | -- | ||||
| Depreciation expense | 2 | 2 | ||||
| Amortization expense | 10 | 10 | ||||
| Mark-to-market warrant expense | 15 | 15 | ||||
| Premium deficiency reserve | 14 | 14 | ||||
| Transaction expense, Business Combinations | 35 | 35 | ||||
| Transaction related litigation fees | 11 | 11 | ||||
| Stock-based compensation | 16 | 16 | ||||
| Adjusted EBITDA PMPM | $ | (120 | ) | $ | (115 | ) |
| 以 PMPM 美元爲單位 | 初步未經審計 | |||||
| 截至該年度 | ||||||
| 2021年12月31日 | ||||||
| 較低的射程 | 上限範圍 | |||||
| 淨收益（虧損）PMPM | $ | (248) | ) | $ | (242 | ) |
| 利息（收入）支出，淨額 | 24 | 24 | ||||
| 所得稅支出(1) | -- | -- | ||||
| 折舊費用 | 2 | 2 | ||||
| 攤銷費用 | 10 | 10 | ||||
| 按市值計價的認股權證費用 | 15 | 15 | ||||
| 保費缺口準備金 | 14 | 14 | ||||
| 交易費用、業務合併 | 35 | 35 | ||||
| 與交易相關的訴訟費 | 11 | 11 | ||||
| 基於股票的薪酬 | 16 | 16 | ||||
| 調整後的息稅折舊攤銷前利潤 PMPM | $ | (120) | ) | $ | (115) | ) |
(1) As of the date of this release, the Company has not finalized its 2021 income tax provision.
(1) 截至本新聞稿發佈之日，該公司尚未最終確定其2021年所得稅條款。
We are not able to provide a reconciliation of guidance for Adjusted EBITDA or Adjusted EBITDA PMPM to net income (loss) or net income (loss) PMPM, the most directly comparable GAAP measures, respectively, and have not provided forward-looking guidance for net income (loss) or net income (loss) PMPM, because of the variability around select items that may impact net income (loss), including stock-based compensation and mark-to-market warrant expense, that are not within our control or cannot be reasonably predicted without unreasonable effort.
我們無法將調整後的息稅折舊攤銷前利潤或調整後的息稅折舊攤銷前利潤（PMPM）與淨收益（虧損）PMPM（分別是最直接可比的GAAP指標）提供對賬指導，也沒有爲淨收益（虧損）或淨收益（虧損）PMPM提供前瞻性指導，因爲某些項目的波動可能會影響淨收益（虧損），包括股票薪酬和加值按市價計算的認股權證費用，這些費用不在我們的控制範圍內，或者如果不作出不合理的努力就無法合理預測。
Key Performance Metrics
In addition to our GAAP and non-GAAP financial information, the Company also monitors "at risk members" to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. At-risk membership represents the approximate number of Medicare Advantage members for whom we receive a fixed per member per month fee under capitation arrangements as of the end of a particular period.
關鍵績效指標
除了我們的GAAP和非GAAP財務信息外，公司還監控 “風險成員”，以幫助我們評估業務，確定影響我們業務的趨勢，制定業務計劃並做出戰略決策。風險會員資格代表截至特定期限結束時，我們根據人頭安排向每位會員每月收取固定費用的Medicare Advantage會員的大致人數。
Financial Disclosure Advisory
The Company reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). The expected financial results discussed in this press release are preliminary and represent the most current information available to the Company's management, as financial closing procedures for the fourth quarter and full year ended December 31, 2021, are not yet complete. These estimates are not a comprehensive statement of the Company's financial results for the fourth quarter and full year ended December 31, 2021, and actual results may differ materially from these estimates as a result of the completion of year-end accounting procedures and adjustments, including the execution of the Company's internal control over financial reporting, the completion of the preparation and audit of the Company's financial statements and the subsequent occurrence or identification of events prior to the formal issuance of the audited financial statements for full year 2021.
財務披露諮詢
公司根據美國公認會計原則（“GAAP”）報告其財務業績。本新聞稿中討論的預期財務業績是初步的，代表了公司管理層掌握的最新信息，因爲截至2021年12月31日的第四季度和全年財務結算程序尚未完成。這些估計不是公司截至2021年12月31日的第四季度和全年財務業績的全面報表，實際業績可能與這些估計存在重大差異，這是因爲年終會計程序和調整已經完成，包括公司對財務報告的內部控制的執行，公司財務報表的編制和審計的完成以及經審計的財務報告正式發佈之前隨後發生或發現的事件2021 年全年的報表。
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and strategy. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements address various matters including the Company's future expected growth and strategy; current expectations regarding the COVID-19 pandemic; preliminary expectations as to revenue, net loss and Adjusted EBITDA for the quarter ended December 31, 2021; preliminary expectations as to the number of at-risk Medicare Advantage members, revenue, net loss, net loss PMPM, Adjusted EBITDA and Adjusted EBITDA PMPM for the full year ended December 31, 2021; the Company's outlook as to the number of at-risk Medicare Advantage members, revenue, Adjusted EBITDA and Adjusted EBITDA PMPM for the full year ending December 31, 2022; and expectations to achieve profitability in 2024, all of which reflect the Company's expectations based upon currently available information and data. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.
前瞻性陳述
本新聞稿包含經修訂的1933年《證券法》第27A條、經修訂的1934年《證券交易法》第21E條和經修訂的1995年《私人證券訴訟改革法》所指的前瞻性陳述。這些前瞻性陳述包括有關我們未來增長和戰略的陳述。諸如 “預測”、“相信”、“預算”、“考慮”、“繼續”、“可能”、“設想”、“預期”、“指導”、“表明”、“打算”、“可能”、“可能”、“可能”、“潛力”、“預測”、“可能”、“預期”、“項目”、“尋找” 之類的詞語 “應該”、“目標” 或 “將”，或其負面或其他變體，以及相似的詞語或短語或類似術語，旨在識別前瞻性陳述。這些前瞻性陳述涉及各種問題，包括公司未來的預期增長和戰略；當前對 COVID-19 疫情的預期；對截至2021年12月31日的季度收入、淨虧損和調整後息稅折舊攤銷前利潤的初步預期；對截至2021年12月31日的全年面臨風險的Medicare Advantage成員數量、收入、淨虧損、淨虧損、PMPM、調整後息稅折舊攤銷前利潤和調整後息稅折舊攤銷前利潤 PMPM 的初步預期；公司的展望至於處境危險的Medicare Advantage成員的數量，收入，截至2022年12月31日的全年調整後的息稅折舊攤銷前利潤和調整後的息稅折舊攤銷前利潤（PMPM）；以及對2024年實現盈利的預期，所有這些都反映了公司基於當前可用信息和數據的預期。由於此類陳述基於對未來財務和經營業績的預期，而不是事實陳述，因此實際業績可能與預期或估計的結果存在重大差異，因此提醒您不要過分依賴這些前瞻性陳述。這些前瞻性陳述不能保證未來的業績、狀況或結果，涉及許多已知和未知的風險、不確定性、假設和其他重要因素，其中許多是公司無法控制的，這些因素可能導致實際業績或結果與前瞻性陳述中討論的結果或結果存在重大差異。
Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to continue our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payers; the impact of COVID-19 or another pandemic, epidemic or outbreak of infectious disease on our business and results of operation; and our ability to recruit and retain qualified team members and independent physicians; and other factors discussed in the "Risk Factors" section of the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission ("SEC") on December 28, 2021 and in the Company's other filings with the SEC. All information in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. You are cautioned not to place undue reliance on any forward-looking statements contained in this press release.
可能導致我們的實際業績和財務狀況與前瞻性陳述中指出的存在重大差異的重要風險和不確定性包括：市場或行業狀況、監管環境、競爭條件和對我們服務的接受程度的變化；我們繼續增長和擴大業務的能力；適用於我們業務的法律法規的變化；我們維持與健康計劃和其他主要付款人關係的能力；COVID-19 或其他疫情、流行病的影響或傳染病疫情影響我們的業務和經營業績；以及我們招募和留住合格團隊成員和獨立醫生的能力；以及公司於2021年12月28日向美國證券交易委員會（“SEC”）提交的S-1表格註冊聲明的 “風險因素” 部分以及公司向美國證券交易委員會提交的其他文件中討論的其他因素。本新聞稿中的所有信息均截至本文發佈之日，除非法律要求，否則我們沒有義務更新或修改這些信息。提醒您不要過分依賴本新聞稿中包含的任何前瞻性陳述。
Contacts
Kelley Waynert, Senior Manager, Strategic Communications
P3 Health Partners
(702) 334-6745
KWaynert@p3hp.org
聯繫人
凱利·韋納特，戰略傳播高級經理
P3 健康合作伙伴
(702) 334-6745
KWaynert@p3hp.org
Investor Relations
Cody Slach, Alex Kovtun
Gateway Group
(949) 574-3860
PIII@gatewayir.com
投資者關係
Cody Slach、Alex Kovtun
網關組
(949) 574-3860
PIII@gatewayir.com
Public Relations
Zach Kadletz, Natalie Balladarsch
Gateway Group
(949) 574-3860
PIII@gatewayir.com
公共關係
Zach Kadletz、Natalie Balladarsch
網關組
(949) 574-3860
PIII@gatewayir.com
